Advanced Ovarian Cancer Treatment: Recent Updates in the Second- and Later-Line Maintenance Settings

Robert L Coleman, MD, FACOG, FACS, and Bradley J Monk, MD, FACOG, FACS, provide an overview of advanced ovarian cancer and discuss its prevalence and diagnosis process.

Experts on advanced ovarian cancer give detailed insights on the role of biomarker testing and identify important biomarkers.

Expert oncologists give an overview of PARP inhibitors available for the treatment of patients with advanced ovarian cancer and review adverse events seen with each agent.

Drs Coleman and Monk discuss what led to the recent withdrawal of several indications for PARP inhibitors in the treatment of advanced ovarian cancer.

Expert oncologists review the current PARP inhibitor treatment indications for patients with advanced ovarian cancer and discuss how to best manage patients who have been impacted by the recent updates to the PARP inhibitors.

Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.